36.38 +0.05 (0.14%)
After hours: 6:22PM EDT
|Bid||36.20 x 500|
|Ask||36.38 x 500|
|Day's Range||36.08 - 36.80|
|52 Week Range||31.67 - 39.43|
|PE Ratio (TTM)||10.33|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||1.36 (3.70%)|
|1y Target Est||40.15|
Pfizer Inc. and Astellas Pharma Inc. announced today that a supplemental New Drug Application for XTANDI® has been accepted for filing and granted Priority Review designation by the U.S.
sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC NEW YORK and TOKYO , March 19, 2018 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President ...
J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.
In March 2017, Merck (MRK) and Eisai entered into a collaboration to jointly develop and commercialize Lenvima, a TK (tyrosine kinase) inhibitor developed by Eisai. Merck and Eisai entered into the collaboration to jointly develop and commercialize Lenvima as monotherapy and in combination with Merck’s Keytruda. Lenvima is approved as a monotherapy for the treatment of thyroid cancer.
Let's see if Pfizer Inc. (PFE) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
SAN DIEGO, March 19, 2018 /PRNewswire/ -- BioDuro LLC, a global life science research and development organization, announces the creation of AISF ([4-(Acetylamino)phenyl]-ImidodiSulfuryl diFluoride), a convenient, shelf-stable, crystalline reagent for the synthesis of fluorosulfates and sulfamoyl fluorides. AISF was developed through a research collaboration with Pfizer Inc. (PFE).
Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
In 4Q17, Merck’s (MRK) Invanz generated revenues of $157 million, which represents a ~3% rise on a YoY (year-over-year) basis and a 1% decline on a QoQ (quarter-over-quarter). In 4Q17, in the US and in international markets, Invanz generated revenues of $93 million and $64 million, respectively, compared with $90 million and $63 million in 4Q16, which represents a ~4% rise and a ~2% rise, respectively, YoY. In 2017, Invanz reported revenues of $602 million, compared with $561 million in 2016, which is ~7% higher YoY.
Pfizer Inc. boosted Chief Executive Officer Ian Read’s compensation for 2017 to $27.9 million, a 61 percent increase, to ensure he stays on the job.
This week I discuss two dividend paying companies that both beat top and bottom line expectations and are expected to greatly benefit from the new tax reform law over the next few years. These companies are Pfizer Inc. (PFE), and Delta Air lines Inc. (DAL).
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis but 1% higher on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Cubicin generated revenues of $40 million and $52 million, respectively, compared with $82 million and $36 million in 4Q16, which reflected a ~51% decline and 43% rise, respectively, YoY. In fiscal 2017, Cubicin reported revenues of $382 million, compared with $1.1 billion in 2016.